mCRC
Conditions
Keywords
Irinotecan, Oxaliplatin, refractory, mCRC
Brief summary
This is a prospective, open-lable, multicenter, randomized, controlled, phase II clinical study. The aim is to evaluate the efficacy of Irinotecan versus Oxaliplatin in the first-line treatment of refractory metastatic colorectal cancer.
Detailed description
This trial is conducted in patients with the refractory metastatic colorectal cancer. Eligible patients are randomized into two arms at 1:1 ratio to receive Irinotecan-based regimen or Oxaliplatin-based regimen until progress of the disease, unacceptable toxicity or withdrawal of consent by the patient. Study evaluation time is until death of patient or a deadline set by the researchers.
Interventions
DRUGIrinotecan
Irinotecan 180 mg / m2, intravenous drip, D1, combined with fluorouracil / calcium folinate or Capecitabine or S1; combine or not combine with Bevacizumab or Cetuximab; every 14 days for a cycle.
DRUGOxaliplatin
Oxaliplatin 85mg/m2 (two-week regimen) or 130mg/m2 (three week regimen), intravenous drip, D1, combined with fluorouracil / calcium folinate or Capecitabine or S1; combine or not combine with Bevacizumab or Cetuximab; every 14 or 21 days for a cycle.
Sponsors
Liaoning Cancer Hospital & Institute
Zhejiang University
Peking University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histopathological diagnosis of metastatic colorectal adenocarcinoma. 2. At least one measurable or assessable lesion that meet RECIST criteria. 3. Accord with standard for refractory colorectal cancer (The standard for refractory colorectal cancer can be met if one of the following conditions is met) (1) Right colon cancer. (2) Mucinous adenocarcinoma or signet ring cell carcinoma. (3) Complicated by peritoneal metastasis. (4) MSI-H or dMMR, immune checkpoint inhibitor therapy is not acceptable. 4. Male or female, age≥18 years old. 5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. 6. Life expectancy \>3 months 7. Adequate organ function as indicated by the following laboratory values: 1. Serum total bilirubin ≤ 1.5 X upper limit of the normal (ULN) 2. Absolute neutrophil count (ANC) ≥1,500 /µL（1.5×109 /L） 3. Platelets ≥100,000 /µL（100×109 /L） 4. Hemoglobin ≥9.0 g/dL 5. Serum creatinine ≤1.5 X (ULN) 6. Prothrombin Time (PT)≤ 1.5 X ULN 7. Left ventricular ejection fraction (LVEF)(measured by Doppler ultrasound) is greater than the lower limit of the normal value (LLN) defined by the study center at which the examination was conducted. 8\. Signed the informed consent with name and time. 9. The subjects are accredited with good compliance, and capable to cooperate, completing the relevant examination treatment, and follow-ups.
Exclusion criteria
1. Received palliative chemotherapy, such as adjuvant chemotherapy, recurrence within 12 months after adjuvant chemotherapy. 2. Metastatic lesion is subject to be treated by local intervention. 3. Subjects with BRAF V600E mutation. 4. Presence of other active malignancies or a history of other malignancies within the past 5 years, except for carcinoma in situ of the cervix, basal cell carcinoma of the skin that has been previously treated with curative intent. 5. Subjects with cerebral metastasis, spinal cord compression, carcinomatous meningitis, CT /MRI examination reveals diseases of the brain or pia mater during screening. 6. Subjects with chronic diarrhea, intestinal obstruction or incomplete intestinal obstruction, or severe peripheral nerve disease. 7. Any of the following diseases occurred in the 12 months before the study: Myocardial infarction, severe / unstable angina pectoris, coronary artery / peripheral artery bypass grafting, symptomatic congestive heart failure, cerebrovascular accident, or transient ischemic attack, or pulmonary embolism within 6 months 8. Subject is known to be infected with Immunodeficiency virus (HIV) or associated with acquired immune deficiency syndrome (AIDS). 9. Subject is enrolled in other clinical trials currently. 10. Pregnant or lactating women; women of potential childbearing age and male subjects do not use effective contraception during the study period. 11. Other severe acute and chronic physiological or mental problems, or abnormal laboratory tests, which may increase the risk of participating in the study or use of drugs, or interfering with the results of the study, and is judged by the researchers that the patient is not suitable for the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first. | assessed up to 10 months | Evaluation of the Progression-free Survival of Irinotecan-based regimen versus Oxaliplatin-based regimen in refractory metastatic colorectal cancer patients. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of treatment related emergent adverse events（Safety and Tolerance） | Until 28 days after the deadline of enrollment | Adverse reactions evaluation is based on the National Cancer Institute adverse event General terminology Standard \[CTCAE\] 4.0 version |
| Overall Survival : From date of enrollment until the date of death. | 2 years | Evaluation of the Overall Survival of Irinotecan-based regimen versus Oxaliplatin-based regimen in refractory metastatic colorectal cancer patients. |
| Evaluation of PFS in patients with different fluorouracil drugs and different genotyping subgroups. | 10months | flurouracil drugs：fluorouracil、S1、Capecitabine |
| Evaluation of OS in patients with different fluorouracil drugs and different genotyping subgroups. | 2 years | flurouracil drugs：fluorouracil、S1、Capecitabine |
Countries
China
Outcome results
None listed